GlassScriptPhysician profile
Wilson M Parry
NPI 1124188347
$5,999.72
in general payments reported to CMS, 2019-2025
23 companies · $682 in 2025
The $682 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $667 · 2020: $452 · 2021: $951 · 2022: $1,190 · 2023: $1,101 · 2024: $957 · 2025: $682.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,636 · Education: $104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,635.83 |
| Education | $104.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,034.16 | 2019-2025 | Farxiga, Lokelma |
| Akebia Therapeutics INC | $719.29 | 2019-2025 | Auryxia, Vafseo |
| Nxstage Medical, INC. | $648.09 | 2020-2025 | Nxstage System One |
| Bayer Healthcare Pharmaceuticals INC. | $448.85 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $414.68 | 2021-2024 | Acthar |
| Amgen INC. | $407.36 | 2019-2025 | Tavneos, Parsabiv, Aranesp |
| Fresenius USA Marketing, INC. | $401.06 | 2019-2025 | Velphoro |
| Aurinia Pharma U.S., INC. | $381.20 | 2021-2025 | Lupkynis |
| Novo Nordisk INC | $251.12 | 2020-2025 | Ozempic, Wegovy |
| Vifor Pharma, INC. | $163.65 | 2019-2022 | |
| Ardelyx, INC. | $149.53 | 2024-2025 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.92 | 2024-2025 | Jardiance |
| Melinta Therapeutics, LLC | $123.49 | 2019 | |
| Alexion Pharmaceuticals, INC. | $123.28 | 2019 | |
| Ani Pharmaceuticals, INC. | $118.60 | 2022-2023 | Purified Cortrophin Gel |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $97.50 | 2021 | |
| Glaxosmithkline, LLC. | $90.04 | 2022-2023 | Benlysta |
| Bard Peripheral Vascular, INC. | $81.26 | 2022 | |
| Medtronic, INC. | $68.21 | 2024 | Ellipsys Vascular Access System |
| Baxter Healthcare | $61.27 | 2022 | |
| Novartis Pharmaceuticals Corporation | $56.14 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $19.29 | 2020 | |
| Lilly USA, LLC | $16.73 | 2024 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wilson Parry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.